• Health & Medicine
• Science & Technology

CRT and ValiRx sign licensing deal to develop prostate cancer treatment

CANCER RESEARCH TECHNOLOGY has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer. CANCER RESEARCH TECHNOLOGY has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.

12 August 2010

• Health & Medicine
• Science & Technology

Cancer Research UK launches medicine manufacturing hub for life-saving research

Cancer Research UK's Drug Development Office marks the launch of its Biotherapeutics Development Unit (BDU) today with the manufacture of its first product - an antibody for treating a range of cancers. Cancer Research UK's Drug Development Office marks the launch of its Biotherapeutics Development Unit (BDU) today with the manufacture of its first product - an antibody for treating a range of cancers.

30 July 2010

• Health & Medicine
• Science & Technology

Treatment reduces dangerous side effects of cancer treatment in children

Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect, according to a major international study published today (Tuesday) in the Journal of Clinical Oncology. Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect, according to a major international study published today (Tuesday) in the Journal of Clinical Oncology.

20 July 2010

• Health & Medicine
• Science & Technology

'Skills Swap' to exploit expertise for patient benefit

Cancer Research Technology (CRT) and Medical Research Council Technology (MRCT) will 'swap' medical discoveries to accelerate the translation of early scientific research into patient benefit. Cancer Research Technology (CRT) and Medical Research Council Technology (MRCT) will 'swap' medical discoveries to accelerate the translation of early scientific research into patient benefit.

13 July 2010

• Health & Medicine
• Science & Technology

UK-NZ collaboration to home in on new anti-cancer drug for leukaemia

Cancer Research Technology (CRT) - Cancer Research UK's development and commercialisation arm has teamed up with The University of Auckland to advance the discovery of new molecular targeted compounds for the treatment of leukaemia. Cancer Research Technology (CRT) - Cancer Research UK's development and commercialisation arm has teamed up with The University of Auckland to advance the discovery of new molecular targeted compounds for the treatment of leukaemia.

22 April 2010

• Science & Technology

CRT announces partnership with Cephalon to co-develop a new class of anti-cancer drugs

Cancer Research Technology (CRT) has announced an exclusive agreement with Cephalon, Inc., an international biotechnology company, to collaborate on the development of small molecule inhibitors. These molecules will target specific members of the Protein Kinase C superfamily of cell signalling proteins - which have been shown to be associated with the development of cancer. Cancer Research Technology (CRT) has announced an exclusive agreement with Cephalon, Inc., an international biotechnology company, to collaborate on the development of small molecule inhibitors. These molecules will target specific members of the Protein Kinase C superfamily of cell signalling proteins - which have been shown to be associated with the development of cancer.

22 March 2010

• Science & Technology

Exploiting cancer's 'double agent' could lead to new treatments for bowel cancer

Cancer Research UK-funded scientists have discovered that the gene defects that cause some bowel cancers could become the targets for new personalised treatments. Their research is published in Cancer Cell today (Monday). Cancer Research UK-funded scientists have discovered that the gene defects that cause some bowel cancers could become the targets for new personalised treatments. Their research is published in Cancer Cell today (Monday).

15 March 2010

• Health & Medicine
• Science & Technology

CRT and AstraZeneca form major alliance to create cancer metabolism drugs

Cancer Research UKїs commercialisation and development arm, Cancer Research Technology (CRT), today announced it has teamed up with biopharmaceutical business, AstraZeneca in a major, multi-project alliance, in which around 30 scientists will be focused on creating a stream of new anti-cancer drugs, it is announced today (Sunday). Cancer Research UKїs commercialisation and development arm, Cancer Research Technology (CRT), today announced it has teamed up with biopharmaceutical business, AstraZeneca in a major, multi-project alliance, in which around 30 scientists will be focused on creating a stream of new anti-cancer drugs, it is announced today (Sunday).

7 February 2010

• Health & Medicine
• Science & Technology

Deal struck for new investigational anti-cancer drug to target leukaemia and lymphoma

CANCER RESEARCH UK and Cancer Research Technology (CRT), the charityїs development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody * drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday). CANCER RESEARCH UK and Cancer Research Technology (CRT), the charityїs development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody * drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday).

4 January 2010

• Health & Medicine
• Science & Technology

Cancer Research UK ploughs Ј21 million into new Drug Discovery Programmes

CANCER RESEARCH UK is set to extend its drug discovery effort by investing up to Ј16 million in two new Drug Discovery Programmes at the Paterson Institute for Cancer Research in Manchester and the Beatson Institute for Cancer Research in Glasgow. CANCER RESEARCH UK is set to extend its drug discovery effort by investing up to Ј16 million in two new Drug Discovery Programmes at the Paterson Institute for Cancer Research in Manchester and the Beatson Institute for Cancer Research in Glasgow.

22 September 2009

• Health & Medicine
• Science & Technology

CRT, Newcastle University and KuDOS advance DNA-PK research with a new licence

Cancer Research Technology Limited (CRT) has licensed the rights to its DNA-dependent protein kinase (DNA-PK)* inhibitor programme to collaboration partner KuDOS Pharmaceuticals Ltd (KuDOS) - a wholly owned subsidiary of AstraZeneca. Cancer Research Technology Limited (CRT) has licensed the rights to its DNA-dependent protein kinase (DNA-PK)* inhibitor programme to collaboration partner KuDOS Pharmaceuticals Ltd (KuDOS) - a wholly owned subsidiary of AstraZeneca.

15 May 2009

• Health & Medicine
• Science & Technology

Temozolomide sales reach $1 billion

Sales of Temozolomide*, an anti-cancer drug developed by Cancer Research UK scientists, have reached $1 billion**. Sales of Temozolomide*, an anti-cancer drug developed by Cancer Research UK scientists, have reached $1 billion**.

6 February 2009